English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/40180
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Title

Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism

AuthorsJazwa, Agnieszka; Rojo, Ana I. ; Innamorato, Nadia G.; Hesse, Marlen; Fernández-Ruiz, Javier; Cuadrado, Antonio
KeywordsOxidative stress
Sulforaphane
Mice
Neuroinflammation
Astrocytes
Pathway
Issue Date1-Jun-2011
PublisherMary Ann Liebert
CitationAntioxidants and Redox Signalling 14(12): 2347-2360 (2011)
AbstractCurrent therapies for motor symptoms of Parkinson's disease (PD) are based on dopamine replacement. However, the disease progression remains unaffected, because of continuous dopaminergic neuron loss. Since oxidative stress is actively involved in neuronal death in PD, pharmacological targeting of the antioxidant machinery may have therapeutic value. Here, we analyzed the relevance of the antioxidant phase II response mediated by the transcription factor NF-E2-related factor 2 (Nrf2) on brain protection against the parkinsonian toxin methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Intraperitoneal administration of the potent Nrf2 activator sulforaphane (SFN) increased Nrf2 protein levels in the basal ganglia and led to upregulation of phase II antioxidant enzymes heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase (NQO1). In wild-type mice, but not in Nrf2-knockout mice, SFN protected against MPTP-induced death of nigral dopaminergic neurons. The neuroprotective effects were accompanied by a decrease in astrogliosis, microgliosis, and release of pro-inflammatory cytokines. These results provide strong pharmacokinetic and biochemical evidence for activation of Nrf2 and phase II genes in the brain and also offer a neuroprotective strategy that may have clinical relevance for PD therapy.
Publisher version (URL)http://dx.doi.org/10.1089/ars.2010.3731
URIhttp://hdl.handle.net/10261/40180
DOI10.1089/ars.2010.3731
ISSN1523-0864
E-ISSN1557-7716
Appears in Collections:(IIBM) Artículos
Files in This Item:
File Description SizeFormat 
Pharmacological Targeting.pdf2,33 MBAdobe PDFThumbnail
View/Open
Show full item record
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.